A platform to advance innovation in drug delivery and facilitate best practice in formulation
The only formulation and drug delivery event…
- Where the agenda brings together 20+ VP/ Director level industry experts from leading pharmaceutical manufacturing companies
- With dedicated streams of formulation and drug delivery, to enable you to tailor the experience to your specific needs
- With unrivalled networking opportunities with senior level members of the drug development community
Join us next year in Amsterdam, to see focused and detailed presentations of innovative pharmaceutical research and real life case studies from senior level formulation and drug delivery experts. With two dedicated streams, interactive round table discussions and pre-conference workshops, the event will create an unrivalled opportunity for advancement in this field.
A little taster of what’s to come…
Last year’s testimonials:
"Very good, very high level in every direction, skills of presentation, content of presentation, slides. Highly valuable on the learning about amorphous practical cases & theoretical approach"
Dr Daniele Schott, Solvias AG
"Excellent talks. All presentations were interesting, detailed & well explained. Extremely valuable-I've learned a lot about amorphous characterisation, generation & control"
Caitriona Cashell, GlaxoSmithKline
"A high standard of speakers present. Very good at giving me an idea of the co-crystal landscape in preparation, application & legal fields"
Noel Hamill, Almac Sciences
"Overall very strong. Very valuable, would come back"
Joe Lubach, Genentech
"The conference was “perfect” in my personal opinion. From last year I have received 2 orders that started during the meeting. I hope we can at least repeat this number based on this conference. I don"t have a total overview yet, but I think we have picked up about 10 leads and at least 30 great contacts"
Michel Bökkerink, Sales Director Systems Europe, Avantium Technologies
Brendan Griffin, University of Cork, talks on advancements in Lipid Based Formulations:
With the drive to develop new and innovative new medicines, there is a distinct trend towards lead drug candidates that display poor oral bioavailability. It is estimated that that between 40-70% of new drug candidates display poor oral absorption characteristics and can therefore result in development delays and/or failure of drug approval for the oral dosage form. Lipid-based drug delivery systems (LBDDS) have the potential to overcome these formulation challenges.
While the emergence of all many commercial examples of lipid-based formulations represents an impressive return over the last 15 years, the general scientific opinion is that the full potential of lipid-based formulations remains untapped.
However, the emergence of novel excipients with acceptable regulatory and safety profiles coupled with the advances in formulation technologies have improved the potential to further develop successful lipid-based formulations. This presentation outlines the design of such lipid-based technologies. The mechanisms whereby these formulations enhance the absorption of poorly soluble drugs are discussed.
Dr. Norbert Rasenack, Novartis Pharma, talks about the opportunities of Continuous Manufacturing to improve drug development:
Continuous Manufacturing Technologies enable opportunities in pharmaceutical production, but also within Pharmaceutical Development and Clinical Trial Medication Manufacture. “Ultra-lean” manufacturing strategies enable economic benefit compared to conventional “batch” manufacture. This presentation will give an overview on motivations to implement continuous manufacturing technologies for oral solid dosage forms within the pharmaceutical industry, and will give insights into CM technologies including QC aspects, and outline the current status of CM within Pharma, and its impact in future.